Abstract
W. Graham E. Cooksley, MD, explores the place that interferon currently holds in the therapeutic armamentarium against hepatitis B.
MeSH terms
-
Adenine / administration & dosage
-
Adenine / adverse effects
-
Adenine / analogs & derivatives*
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / adverse effects
-
Clinical Trials as Topic
-
Hepatitis B / diagnosis*
-
Hepatitis B / therapy*
-
Humans
-
Interferon-alpha / administration & dosage*
-
Interferon-alpha / adverse effects
-
Lamivudine / administration & dosage*
-
Lamivudine / adverse effects
-
Organophosphonates / administration & dosage*
-
Organophosphonates / adverse effects
-
Patient Selection
-
Practice Guidelines as Topic
-
Practice Patterns, Physicians'
-
Prognosis
-
Risk Assessment / methods*
-
Risk Factors
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Interferon-alpha
-
Organophosphonates
-
Lamivudine
-
adefovir
-
Adenine